Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

CRGX CARGO Therapeutics Inc

Price (delayed)

$4.55

Market cap

$209.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.62

Enterprise value

$177.93M

We are a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients. Our programs, platform technologies, and manufacturing strategy are designed to directly ...

Highlights
The EPS has plunged by 168% YoY and by 24% from the previous quarter
The net income has dropped by 78% year-on-year and by 29% since the previous quarter

Key stats

What are the main financial stats of CRGX
Market
Shares outstanding
46.11M
Market cap
$209.82M
Enterprise value
$177.93M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.74
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$234.99M
Net income
-$216.19M
EBIT
-$216.19M
EBITDA
-$209.75M
Free cash flow
-$150.61M
Per share
EPS
-$4.62
EPS diluted
-$4.62
Free cash flow per share
-$3.15
Book value per share
$6.13
Revenue per share
$0
TBVPS
$7.56
Balance sheet
Total assets
$361.96M
Total liabilities
$79.5M
Debt
$30.45M
Equity
$282.46M
Working capital
$273.26M
Liquidity
Debt to equity
0.11
Current ratio
6.3
Quick ratio
6.2
Net debt/EBITDA
0.15
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-50.4%
Return on equity
-58.4%
Return on invested capital
-63.8%
Return on capital employed
-69.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRGX stock price

How has the CARGO Therapeutics stock price performed over time
Intraday
1.11%
1 week
10.17%
1 month
5.32%
1 year
-76.26%
YTD
-68.45%
QTD
11.79%

Financial performance

How have CARGO Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$234.99M
Net income
-$216.19M
Gross margin
N/A
Net margin
N/A
The operating income has plunged by 92% YoY and by 25% from the previous quarter
The net income has dropped by 78% year-on-year and by 29% since the previous quarter

Price vs fundamentals

How does CRGX's price correlate with its fundamentals

Growth

What is CARGO Therapeutics's growth rate over time

Valuation

What is CARGO Therapeutics stock price valuation
P/E
N/A
P/B
0.74
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 168% YoY and by 24% from the previous quarter
CRGX's P/B is 51% below its last 4 quarters average of 1.5
CARGO Therapeutics's equity has decreased by 24% YoY and by 22% from the previous quarter

Efficiency

How efficient is CARGO Therapeutics business performance
CRGX's return on invested capital has surged by 50% year-on-year but it is down by 35% since the previous quarter
CARGO Therapeutics's ROE has decreased by 37% from the previous quarter but it has increased by 28% YoY
CARGO Therapeutics's ROA has decreased by 34% from the previous quarter and by 6% YoY

Dividends

What is CRGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRGX.

Financial health

How did CARGO Therapeutics financials performed over time
The company's quick ratio has shrunk by 63% YoY and by 54% QoQ
CRGX's current ratio has dropped by 62% year-on-year and by 54% since the previous quarter
The debt is 89% smaller than the equity
The debt to equity has increased by 38% since the previous quarter and by 38% year-on-year
CARGO Therapeutics's equity has decreased by 24% YoY and by 22% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.